Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongyu Ding

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
EMBO Molecular Medicine|March 12, 2015
A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potencyChuan Liu, Hongyu Ding, Xiaoxi Li, et al.
Cardiovascular Diabetology|February 3, 2024
Revisiting an old relationship: the causal associations of the ApoB/ApoA1 ratio with cardiometabolic diseases and relative risk factors-a mendelian randomization analysisChao Fu, Dongbo Liu, Qi Liu, et al.
Protein & Cell|July 15, 2020
SHANK2 is a frequently amplified oncogene with evolutionarily conserved roles in regulating Hippo signalingLiang Xu, Peixue Li, Xue Hao, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 5, 2026
Liraglutide Ameliorates Injury-Related Vascular Repair by Activating Autophagy Through Modulation of the PI3K-mTOR Signaling PathwayZongyi Zhang, Guixian Wu, Chaozhi Xu, et al.
Nature Communications|April 22, 2022
High-entropy induced a glass-to-glass transition in a metallic glassHengwei Luan, Xin Zhang, Hongyu Ding, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancerRay Pillai, Sarah E LeBoeuf, Yuan Hao, et al.
Science Advances|March 27, 2024
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancerRay Pillai, Sarah E LeBoeuf, Yuan Hao, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
EMBO Molecular Medicine|March 12, 2015
A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potencyChuan Liu, Hongyu Ding, Xiaoxi Li, et al.
Cardiovascular Diabetology|February 3, 2024
Revisiting an old relationship: the causal associations of the ApoB/ApoA1 ratio with cardiometabolic diseases and relative risk factors-a mendelian randomization analysisChao Fu, Dongbo Liu, Qi Liu, et al.
Protein & Cell|July 15, 2020
SHANK2 is a frequently amplified oncogene with evolutionarily conserved roles in regulating Hippo signalingLiang Xu, Peixue Li, Xue Hao, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 5, 2026
Liraglutide Ameliorates Injury-Related Vascular Repair by Activating Autophagy Through Modulation of the PI3K-mTOR Signaling PathwayZongyi Zhang, Guixian Wu, Chaozhi Xu, et al.
Nature Communications|April 22, 2022
High-entropy induced a glass-to-glass transition in a metallic glassHengwei Luan, Xin Zhang, Hongyu Ding, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancerRay Pillai, Sarah E LeBoeuf, Yuan Hao, et al.
Science Advances|March 27, 2024
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancerRay Pillai, Sarah E LeBoeuf, Yuan Hao, et al.
Pageof 4